Clarivate Plc, an information services and analytics company, provides structured information and analytics for discovery, protection, and commercialization of scientific research, innovations, and brands. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis and Newport Integrity for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs. The company also provides Derwent products, which include Derwent Innovation, Techstreet, and IP Professional Services that enables its customers to evaluate the novelty of potential new products, confirm freedom to operate with respect to their product design, help them secure patent protection, assess the competitive technology landscape, and ensure that their products comply with required industry standards; CompuMark products, such as trademark screening, searching, and watching products and services for businesses and law firms; and MarkMonitor products, which helps enterprises to establish, manage, optimize, and protect their online presence. It serves government and academic institutions, life science companies, and research and development corporations in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc is headquartered in London, the United Kingdom.

Clarivate Plc

Healthcare Business Insights, Part of Clarivate

CPA Global

Dialog Solutions (now Clarivate)

Markpro

Clarivate for Life Sciences & Healthcare

Clarivate for Intellectual Property

Derwent_UI/UX_early_look

Clarivate is a leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription- and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit clarivate.com.​ 

Clarivate

Ed Guntin, President and Managing Partner of Guntin & Gust, recently shared how FoundationIP has been a game-changer for his firm. Learn how this solution has forged client relationships and made his renowned Chicago-based IP law firm as trusted Clarivate partner: https://lnkd.in/gtPpskS6

#ThinkForward #Customerstories #IP

We kicked off 2024 by bringing our colleagues around the world together and inspire a Think forward mindset. We look forward to another year leading the innovation lifecycle, sharing insights from our experts and making a lasting impact on the world.

#TeamBuilding #ThinkForward

"New modalities, underpinned by scientific breakthroughs in the past decade, are achieving clinical successes and providing treatments for patients with previously unmet medical needs." - Henry Levy, President, Clarivate for Life Sciences & Healthcare

Explore the 13 new therapeutics featured on Drugs to Watch 2024 report with standout commercial and clinical potential on our blog: https://lnkd.in/gVzE4hEc

#ThinkForward #DrugstoWatch2024 #Healthcare

Explore the world of innovation and uncover awe-inspiring stories on Ideas to Innovation - Season 3. Each episode is packed with creative problem-solving strategies that lead to real-world applications on groundbreaking ideas. Hear from industry experts as they delve into their first-hand experiences, sharing their valuable insights and unique perspectives. Listen today: https://lnkd.in/gWE4duzT

Apple Podcasts: https://lnkd.in/gABCFQX
Spotify: https://lnkd.in/gukez4Ra

#ThinkForward #Innovation #Podcasts

Clarivate releases the 11th annual Drugs to Watch report identifying thirteen potential blockbuster drugs and game changers, including therapeutic advancements for breast cancer, RSV, sickle cell disease and Crohn's. 
 
"Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year’s Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have a transformational impact on patient outcomes.” - Mike Ward, Global Head of Thought Leadership, Clarivate for Life Sciences & Healthcare
 
Read forecasting insights in the full report: https://lnkd.in/grheDDiA
  
#ThinkForward #DrugstoWatch #Healthcare

NYSE:CLVT

Clarivate

Last Close

6.94

03/05 17:09

Market Cap

5.94B

Beta: 1.10

Volume Today

1.04M

Avg: 5.55M

PE Ratio

−31.73

PFCF: 12.47